Development of Mathematical Models for the Analysis of Hepatitis Delta Virus Viral Dynamics by de Sousa, Bruno C. & Cunha, Celso
Development of Mathematical Models for the Analysis of
Hepatitis Delta Virus Viral Dynamics
Bruno C. de Sousa
1*, Celso Cunha
2
1Centre for Malaria and Tropical Diseases, Associated Laboratory, Unit of Epidemiology and Biostatistics, Instituto de Higiene e Medicina Tropical - Universidade Nova de
Lisboa, Lisbon, Portugal, 2Centre for Malaria and Tropical Diseases, Associated Laboratory, Molecular Biology Unit, Instituto de Higiene e Medicina Tropical - Universidade
Nova de Lisboa, Lisbon, Portugal
Abstract
Background: Mathematical models have shown to be extremely helpful in understanding the dynamics of different virus
diseases, including hepatitis B. Hepatitis D virus (HDV) is a satellite virus of the hepatitis B virus (HBV). In the liver, production
of new HDV virions depends on the presence of HBV. There are two ways in which HDV can occur in an individual: co-
infection and super-infection. Co-infection occurs when an individual is simultaneously infected by HBV and HDV, while
super-infection occurs in persons with an existing chronic HBV infection.
Methodology/Principal Findings: In this work a mathematical model based on differential equations is proposed for the
viral dynamics of the hepatitis D virus (HDV) across different scenarios. This model takes into consideration the knowledge
of the biology of the virus and its interaction with the host. In this work we will present the results of a simulation study
where two scenarios were considered, co-infection and super-infection, together with different antiviral therapies.
Although, in general the predicted course of HDV infection is similar to that observed for HBV, we observe a faster increase
in the number of HBV infected cells and viral load. In most tested scenarios, the number of HDV infected cells and viral load
values remain below corresponding predicted values for HBV.
Conclusions/Significance: The simulation study shows that, under the most commonly used and generally accepted
therapy approaches for HDV infection, such as lamivudine (LMV) or ribavirine, peggylated alpha-interferon (IFN) or a
combination of both, LMV monotherapy and combination therapy of LMV and IFN were predicted to more effectively
reduce the HBV and HDV viral loads in the case of super-infection scenarios when compared with the co-infection. In
contrast, IFN monotherapy was found to reduce the HDV viral load more efficiently in the case of super-infection while the
effect on the HBV viral load was more pronounced during co-infection. The results suggest that there is a need for
development of high efficacy therapeutic approaches towards the specific inhibition of HDV replication. These approaches
may additionally be directed to the reduction of the half-life of infected cells and life-span of newly produced circulating
virions.
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Introduction
Hepatitis delta virus (HDV) is considered to be a satellite virus
of the hepatitis B virus (HBV). HDV co-infects or super-infects
liver cells already infected with HBV resulting in an higher risk of
cirrhosis and fulminant hepatitis, as well as increased liver tissue
damage [1,2]. Hepatitis delta virus contains a ribonucleprotein
core which includes a 1.7 Kb circular single-stranded RNA
genome and several copies of the only virus encoded protein, the
so called delta antigen (reviewed in Taylor, [3]). The clinical
association between HDV and HBV is due to the fact that the
outer envelope of HDV consists of the surface antigens coded by
the HBV genome (HBsAgs) which are necessary for virion
maturation and release from the cells (reviewed by Taylor in
[4]). Therefore, productive HDV infection occurs only in the
presence of HBV.
It is widely accepted that the clinical course of super-infection
and co-infection displays distinct features. In most cases, super-
infection of chronic HBV patients results in the development of
chronic HDV infection. In general, the clinical course of HDV
super-infection starts with an acute phase which is followed by the
development of chronicity, and finally the elimination of HDV
and HBV. During the acute phase of infection, an active
replication of HDV is observed whilst HBV replication is partially
suppressed. The following chronic phase is characterized by a
decrease in HDV replication which is accompanied by a
subsequent increase in HBV replication [5]. It is estimated that
about 70% of super-infected patients will progress from acute to
chronic disease. Additionally, 60–79% of chronic HDV patients
will further develop cirrhosis. This rate is 3 times higher than that
found in HBV or HCV infected patients alone [6]. According to
Fattovich et al. [7], HDV super-infection leads to a 3 times greater
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of mortality in patients with compensated cirrhosis. In HDV and
HBV co-infections, the clinical course is similar to that observed
during acute HBV infection [8,9].
There is no specific treatment for HDV infection. The most
common therapeutic approach is based on the administration of
interferon-a. However, the clinical response is variable, and in
most cases reversible upon interruption of treatment [10–12]. The
concomitant use of antiviral drugs like ribavirin or lamivudine,
showed no significant benefits in the treatment of hepatitis delta
patients [13–15]. Although these drugs may have some inhibitory
effect on HBV replication, they do not suppress HDV replication
probably due to the fact that HBsAgs expression, at least in part,
seems not to be affected.
Vaccination against HBV protects individuals against HDV co-
infection. Although vaccination programs led to a considerable
reduction in both HBV and HDV prevalence, the two viruses are
still endemic in a number of regions, namely the Amazon basin,
and some African and Asian countries [16]. It is estimated that
worldwide about 350 million people are infected with HBV of
which 5–10% are also co-infected with HDV. HDV and HBV
share the same routes of infection affecting individuals of all age
groups. The most frequent routes of transmission are the sexual
contact and the direct contact with blood or blood products from
infected carriers [17,18].
The use of mathematical models to study dynamics of virus
infections may represent a powerful approach to simulate the
course of infection and predict the potential response to different
therapies. They have been previously developed for a number of
pathologies including HIV, HBV, and HCV [19–21]. More
recently, the mathematical simulation of the spread of HDV and
HBV in a population was reported [22]. However, a mathematical
model to study HDV and HBV dynamics in infected individuals is
still lacking. In this initial work we report the development of
mathematical models to simulate the dynamics of HDV and HBV,
both during co-infection and super-infection, in the presence and
absence of any therapy. Data are presented concerning the
number of predicted infected cells and viral load along the period
of infection.
Methods
To model for the viral dynamics of HDV we considered the
following six variables:
x(t) the number of uninfected cells at time t,
y1(t) the number of HBV infected cells at time t,
y2(t) the number of HDV infected cells at time t,
y3(t) the number of infected cells with both HBV and
HDV at time t,
n1(t) the HBV viral load at time t,
n2(t) the HDV viral load at time t.
The model representing the hepatitis delta virus (HDV) viral
dynamics can be represented in the diagram in Figure 1, followed
by a description of the variables and parameters represented in this
diagram.
he change in the number of uninfected cells x at a certain
moment in time will depend on the constant rate at which these
cells are generated, l; the number of deaths at that time, which is
proportional to the constant death rate of uninfected cells, d; and
the number of infected cells lost by infection with HBV and HDV
Figure 1. Diagram representing the HDV viral dynamics within an individual.
doi:10.1371/journal.pone.0012512.g001
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HDV, b1 and b2, respectively, and to the HBV and HDV viral
loads at that time n1 and n2, respectively.
With respect to the change in the number of y1, HBV infected
cells, at a certain moment in time, its dependency involves the
constant infection rate of HBV, b1, the number of uninfected cells
x and the HBV viral load n1 at that time. Also, the constant death
rate of HBV infected cells, d1; and the infected cells with HBV that
were co-infected with HDV. The later, proportional to the
constant infection rate of HDV, b2, the number of HBV infected
cells, y1, and the HDV viral load, n2, at that time.
Similarly, the change in the number of HDV infected cells at a
certain time, y2, will depend on the constant infection rate of
HDV, b2, the number of uninfected cells x and the HDV viral
load n2 at that time; the constant death rate of HDV infected cells,
d2; and the infected cells with HDV that were co-infected with
HBV at that time which is proportional to the constant infection
rate of HBV, b1, the number of HDV infected cells, y2, and the
HBV viral load, n1, at that time.
The change in the number y3 of infected cells with both HBV
and HDV at a certain time will depend on the number HBV
infected cells that are infected with HDV at that time; the number
HDV infected cells that are infected with HBV at that time; and
the number of uninfected cells that are infected simultaneously
with HBV and HDV, b1b2 min(n1, n2)x, proportional to the
constant infection rates of HBV and HDV and the viral loads of
HBV and HDV.
The change of HBV viral load at a certain time will depend on
the constant HBV virion clearance rate u1, and from both sources
of viral production, i.e. cells that are infected only with HBV and
with both HBV and HDV. From cells only infected with HBV, the
viral load is proportional to the constant HBV viral production
rate k1 and the number of HBV infected cells at that time y1.
From cells infected with both viruses, the viral load is proportional
to the constant HBV viral production rate k3 and the number of
HBV and HDV infected cells at that time y3.
As for the change in HDV viral load, the dependency of this
viral load will also come from the constant HDV virion clearance
rate u2, but now the viral production will only come from cells that
are infected with both HBV and HDV. Therefore, the change of
HDV viral load at a certain moment in time is proportional to the
constant HDV viral production rate k2 and the number of HBV
and HDV infected cells at that time y3.
As a result of the above, the model for the viral dynamics in an
individual infected with HBV and HDV can be expressed as the
following system of six differential equations modeling the changes
in x, yi (i~1, 2, 3) and nj (j~1, 2):
dx(t)
dt
~l{dx(t){ b1n1(t)zb2n2(t)zb1b2 min(n1(t), n2(t)) ½  x(t)
dy1(t)
dt
~b1n1(t)x(t){d1y1(t){b2n2(t)y1(t)
dy2(t)
dt
~b2n2(t)x(t){d2y2(t){b1n1(t)y2(t)
dy3(t)
dt
~b2n2(t)y1(t)zb1n1(t)y2(t)z
b1b2 min(n1(t), n2(t))x(t){d3y3(t)
dn1(t)
dt
~k1y1(t)zk3y3(t){u1n1(t)
dn2(t)
dt
~k2y3(t){u2n2(t)
ð1Þ
Solving the Mathematical Model
The system of differential equations in (1) needs to be solved
numerically. We used the software Matlab 7.5 [23] where we
simulated the behavior of our proposed model considering two
different kinds of infection: co-infection and super-infection. Co-
infection occurs when an individual is simultaneously infected by
HBV and HDV, while super-infection occurs in persons with an
existing chronic HBV infection. Therefore, for a co-infection
scenario the viral dynamics can be modeled simply by the
equations in (1), while for the super-infection scenario, we assumed
that the individual is first infected with HBV and that the infection
of HDV occurs after 200 days (d) of being infected with HBV.
Thus, before 200 d, the model (1) is simplified by the following
model (2) since only the infection with HBV has occurred.
dx(t)
dt
~l{dx(t){b1n1(t)x(t)
dy1(t)
dt
~b1n1(t)x(t){d1y1(t)
dn1(t)
dt
~k1y1(t){u1n1(t)
ð2Þ
In both scenarios, and to obtain a numerical solution for the viral
dynamics expressed by the models (1) and (2), we will need to provide
some initial values for the functions x(0), yi(0) (i~1, 2, 3)a n dnj(0)
(j~1, 2) and the 12 constant rates involved in these models. Unless
mentioned otherwise, we will now present the assumptions con-
sidered in all simulations throughout this study. The values
considered are summarized at the end of this section in Table 1.
Allthe valuesforx,yi (i~1, 2, 3)an dnj (j~1, 2) areexpressedin
number of copies per milliliter of blood. We will consider that at
time 0 there are no cells infected with HBV or HDV, i.e. yi(0)~0
for i~1, 2, 3. Let us assume three different levels of viral load at the
time of infection, t: a low level of infection with nj(t)~400 copies/
mL;amediumlevelofinfectionwith nj(t)~1|104 copies/mL;and
a high level of infection with nj(t)~1|106 copies/mL for j~1, 2.
For co-infection, we have nj(0)~400 for j~1, 2, and for the super-
infection we have n1(0)~400, n2(t)~0 for t[½0, 200),a n d
n2(200)~400. Finally, the number of uninfected cells in an adult
Table 1. Parameters considered in this study and
corresponding values.
Parameter Values Reference
Liver cell number 1|1012 [24]
Blood volume 6000 mL [24]
Cell division rate 0:3%=day [24], [26]
Liver cells half-life 231 days [24], [26]
Virion life-span in plasma 15–92 hours [37], [28]
Infected cells half-life 10–100 days [37], [28]
Infection rate 4|10{10 mL/copies per day [24]
Viral production rate 6.24/day [24]
Virion clearance rate 6.24/day [24]
Mean viral load in equilibrium 3:6|108 copies/mL [24]
Infected cells number 3:75|107 cells/mL [24], [29]
Clearance constant rate 0.65/day [24]
doi:10.1371/journal.pone.0012512.t001
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the average blood volume of an adult is equal to 6000 mL [24],
the number of uninfected cells per mL can be estimated by
x(0)~
1|1012
6000
~1:7|108 cells/mL [24].
The constants in our study were based on the work by Tsiang
and Gibbs in [24] and summarized in what follows. From [25] and
[26] approximately 0.3% of the liver cells in rats go through
mitosis every day. Assuming the same for humans, the constant
rate at which uninfected cells are generated, l, can be estimated by
l~
0:003|(1|1012)
6000
~5|105 cells/mL per day. Since before
infection the liver is in equilibrium, i.e. the number of uninfected
cells is assumed to be constant. Therefore, we have that
dx(t)
dt
~0,
meaning that, at t~0, we have l{dx(0)~0ud~
l
x(0)
~
5|105
1:7|108 ~0:003 d{1. In terms of half-lives d is equal to
ln(2)
0:003
~231 days.
Regarding the virion clearance rates uj, j~1, 2 and the cell
death rates di, i~1, 2, 3, it is easier to interpret them as their
inverse u{1
j and d{1
i , representing the mean life-spans of HBV and
HDV virion in plasma(u{1
j ) and themean life-spans of productively
infected cells with HBV, HDV and both HBV and HDV (d{1
i ),
respectively. Since there is very little known about the dynamics of
the hepatitis delta virus, we considered not only what it is known in
multiplestudieswithHBVand HDVpatients[5,24,27],butalso the
opinions of clinicians and biologists that suggested possible values of
u{1
j in the range of 15 to 92 hours, and for d{1
i values between 10
days and 100 days [28]. In what follows, we consider the following
set of values
15
24
,
24
24
,
37
24
,
92
24

and f10, 15, 20, 50, 100g days
for u{1
j and d{1
i , respectively.
In terms of the k’is, the viral production rates of HBV from
HBV infected cells (i~1), of HDV (i~2) and HBV (i~3) from
cells infected with both HBV and HDV, it is believed that, at least
during some periods of infection, HDV replication will have an
inhibitor effect on the production of mature HBV particles;
therefore, for our study we considered that k1~k2~6:24 d{1,
and when the infection of HDV occurs, the viral production rate
of HBV from cells infected with HBV and HDV, k3, is equal to
c|k1 d{1 with c~0:1(0:1)1 (c varying from 0.1 to 1 with
increments of 0.1), where c~1 represents no inhibition effect. The
value of 6.24 d{1 for k1 was suggested by Tsiang and Gibbs in
[24] considering the fact that, when infection reaches an
equilibrium, we have that ky~un, i.e. the viral production rate
from an infected cell is approximately equal to the virion
clearance. The mean viral load in the equilibrium was considered
to be n~3:6|108 copies/mL, the clearance constant rate
u~0:65~
24
37
and the number of infected cells to be approximately
y~3:75|107 cells/mL. This value was obtained considering
the work of Bianchi, et al. [29] where it was reported that
approximately 5–40% of hepatocytes are infected in chronic HBV
patients. Tsiang and Gibbs in [24] considered then the mean value
of 22.5% and calculated y as
1|1012
6000
|0:225~3:75|107.
The infection rates, bj~4|10{10 mL/copies per day, for
j~1, 2, were also suggested by Tsiang and Gibbs in [24]. They
were determined such that the peak of the primary viremia
occurred 56 days after the infection of an individual.
We also assumed that when the super-infection occurs there is
an extra HBV inoculum at that moment. In our model we
considered values for extra HBV inoculum of the order 400,
1|104 and 1|106 copies/mL, equals to the initial viral load of
HBV.
In the next section we will discuss in detail the results obtained
from the simulations in Matlab 7.5. Although we present only the
graphs considering initial viral loads of 400 copies/mL, the viral
dynamics for all other scenarios is described in this study as well.
Results
The super-infection results
The values of HDV life-span in plasma of patients and of life-
span of HDV infected liver cells are, to our knowledge, unknown.
Although assuming that these values should not be substantially
different from those reported for HBV [5,24] we first decided to
perform a sensitivity analysis of the influence of these parameters
on the dynamics of infection.
For d{1
i ~10 days, none of the values considered for u{1
j ’s
produced scenarios for the super-infection that are clinically
observed since they would predict a spontaneous HDV clearance
soon after infection. Consider, for example, Figure 2 where
d{1
i ~10 days and u{1
j ~92 hours. Unfortunately, the viral load of
HDV and the number of infected cells do not disappear naturally,
as suggested in this figure.
By increasing the mean life-spans of infected cells by 5 days, i.e
d{1
i ~15 days, and maintaining u{1
j ~92 hours, we can observe
the dynamics of the super-infection in Figure 3. Nevertheless, a
biologically irrelevant scenario occurs again for all other values of
u{1
j . See the result of the simulations for u{1
j ~37 hours in
Figure 4.
For values of d{1
i ’s of 50 and 100 days, all the results were
compatible with reported clinical pictures. What the simulations
suggest is that the smaller the values of mean life-spans of
productively infected cells, d{1
i , the higher the values of mean life-
spans of HBV and HDV virion in plasma, u{1
j , needed in order to
obtain biologically relevant scenarios. Similar results were
obtained when the effect of inhibition of HBV replication by
HDV was tested with different values of c up to 1. We decided to
create a finer grid for the values of u{1
j ’s to estimate the
approximate minimum value for the mean life-spans of HBV and
HDV virion in plasma in order to obtain possible biological
observed scenarios. The results can be seen in Table 2.
The results obtained for estimating the minimum values for
u{1
j ’s in order to obtain observable biological scenarios were quite
similar, independent of the initial viral loads for HBV and HDV
and the different values of the inhibition factor c for the viral
production rate of HBV from a cell infected with HBV and HDV.
In Figure 5 we see an example of the grid values considered for
u{1
j ’s, with d{1
i ~15 days, initial viral loads of 400 copies/mL,
and for k3~0:5|k1. It is very clear that values of u{1
j ’s smaller
than 60 hours generate a scenario that is not observed in patients.
The particular effect of the inhibition factor c of the HBV viral
production rate from an infected cell with HBV and HDV,
k3~c|k1, can only be observed for large values of the mean life-
spans of productively infected cells. For example, for d{1
j ~20
days and u{1
j ~92 hours, the higher the value of c (c~1
representing no inhibition), the closer the viral loads of HBV and
HDV are. A more unstable behavior of the viral loads is observed
for greater values of the inhibition (small values of c). The least
number of infected cells is always observed for those only infected
with HBV, followed by the ones only infected with HDV, and
lastly the HBV and HDV infected cells. For higher values of
inhibition, say, greater than 80% (cv0:2), the number of cells
infected only by HDV surpasses the number of cells infected with
HDV Viral Dynamics
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corresponding values of free viral load. In Figure 6 and Figure 7
we can observe this behavior where the inhibition varies from 90%
(c~0:1) to no inhibition, respectively.
Notice that for d{1
i ’s equal to 15 days and u{1
j ’s equal to
92 hours, there is no effect of the parameter c on the results of the
model. Notice how close Figure 8 is to Figure 3, where we had
90% and 10% of inhibition of the HBV viral production in cells
infected with HBV and HDV, respectively. In this case, we see
from Figure 8 that the HDV viral load is always smaller than the
HBV viral load, and that the number of infected cells is highest for
HBV only infected cells, followed by the ones infected with both
HBV and HDV, and lastly by the number of cells only infected
with HDV.
Since all HDV infected patients are also infected with HBV, we
also considered the scenario of extra HBV inoculum occurring
concomitantly with the HDV infection. In our simulations we
considered this extra HBV inoculum to be equal to the viral load
of HDV. The results obtained were the same whether this
supplement of HBV occurs or not.
For all biological relevant scenarios, the simulations here
reported predict the existence of a peak of viral load and number
of infected cells in the beginning of infection. This is particularly
noticeable in the case of HBV. A similar observation was reported
Figure 2. HBV and HDV viral dynamics. HBV Number of uninfected cells (left), infected cells (middle), and viral loads (right). Initial viral loads of
400 copies/mL, d{1
i ~10 days, u{1
j ~92 hours, and a 10% inhibition of the HBV viral production in cells infected with HBV and HDV.
doi:10.1371/journal.pone.0012512.g002
Figure 3. HBV and HDV viral dynamics. Number of uninfected cells (left), infected cells (middle), and viral loads (right). Initial viral loads of 400
copies/mL, d{1
i ~15 days, u{1
j ~92 hours, and a 10% inhibition of the HBV viral production in cells infected with HBV and HDV.
doi:10.1371/journal.pone.0012512.g003
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This feature may represent an artifact of the model although in
woodchuck hepatitis virus (WHV), peaks of viremia in infected
experimental animals were observed during the first weeks of
infection (see for instance [30]).
The co-infection results
Co-infection occurs when the individual is infected with HBV
and HDV at the same time. The results obtained for the co-
infection using model (1) are, in general, very similar to the ones
obtained for super-infection. The differences are essentially based
on the speed at which the individual reaches the peak of infection
and certain behaviors when the infection is in equilibrium. Next,
we will show some of the results obtained for co-infection where
we try to illustrate the similarities and the differences between
these two scenarios.
Consider the example in Figure 3 where d{1
i ~15 days,
u{1
j ~92 hours, initial viral loads of 400 copies/mL and a 10%
inhibition of the HBV viral production in cells infected with HBV
and HDV. In Figure 9 we simulate the co-infection behavior with
n1(0)~n2(0)~400 copies/mL, i.e. the infection of HBV and
HDV occurs at the same time, t~0.
By comparison with Figure 3, we see that while in super-
infection it takes approximately 550 days from the day of infection
with HDV to reach an equilibrium, in the co-infection case, this
equilibrium is reached after 200 days. In all the examples
analyzed, the slope of the line representing the viral load growth
and the number of infected cells with HDV and with both HBV
and HDV is higher for the co-infection.
It is also believed that for HBV and HDV co-infection the
clinical course does not differ from that observed in patients
infected HBV alone [5]. In situations of no inhibition the major
difference for co-infection is the stability of the viral load when the
equilibrium is reached. Compare both the right graphs in Figure 7
and Figure 10 for d{1
i ~20 days, u{1
j ~92 hours. In co-infection
we see that the viral loads for HBV and HDV have a very similar
and rapid behavior, and that the higher number of infected cells
are represented by the cells infected with both viruses, followed by
the ones infected with HBV, and lastly the ones infected only with
HDV, as can be observed in Figure 10. This contrasts with the
very slow growth during the evolution of the disease when super-
infection occurs, resulting in a different behavior of the number of
infected cells. Recall that for the super-infection case, the smaller
number of infected cells occurred for cells infected only with
HBV.
From the results obtained in this study, we can say that the
development of the disease in super-infection is slower than in co-
infection, suggesting that for super-infection a larger window of
time is available before the beginning of therapy. Might that imply
different reactions when therapies are applied? This will be
explored in the following section.
The Model considering Antiviral Therapy
Antiviral therapy will have an impact on HDV viral dynamics
depending on whether it is aimed at eliminating the virus itself
including through modulation of the immune system (i.e.
interferon-a), or inhibiting HBV free virion production (i.e.
lamivudine or ribavirine). Although there is no specific treatment
for HDV infection, there has been some recent successful stories in
treating patients [31]. As mentioned before, the most common
therapeutic approach is based on the administration of peggylated
interferon-a which helps promoting virus clearance. However, the
clinical response is variable, and in most cases reversible upon
Figure 4. HBV and HDV viral dynamics. Number of uninfected cells (left), infected cells (middle), and viral loads (right). Initial viral loads of 400
copies/mL, d{1
i ~15 days and u{1
j ~37 hours, and a 10% inhibition of the HBV viral production in cells infected with HBV and HDV.
doi:10.1371/journal.pone.0012512.g004
Table 2. Estimated minimum values for u{1
j .
d{1
i (days) u{1
j (hours)
10 w118
15 w60
20 w32
doi:10.1371/journal.pone.0012512.t002
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antiviral drugs like ribavirin or lamivudine, which is believed to
reduce the production rate of HBV free virions that are released
from infected cells in the blood, showed no significant benefits in
the treatment of hepatitis delta patients [13–15]. Although these
drugs may have some inhibitory effect on HBV replication, they
do not suppress HDV replication, probably due to the fact that
HBsAgs expression is not significantly affected.
Let g be the efficacy of inhibiting new virus infections as a
consequence of virus clearance, and the efficacy of inhibiting
viral production from infected cells, with both g and in the
interval ½0, 1 . The antiviral impact from the different types of
Figure 5. HBV and HDV viral dynamics. Number of infected cells with HBV, HDV and with both HBV and HDV for different values of u{1
j ’s in
hours and d{1
i ~15 days.
doi:10.1371/journal.pone.0012512.g005
Figure 6. HBV and HDV viral dynamics. Number of uninfected cells (left), infected cells (middle), and viral loads (right). Initial viral load of 400
copies/mL, d{1
i ~20 days and u{1
j ~92 hours, and a 90% inhibition of the HBV viral production in cells infected with HBV and HDV.
doi:10.1371/journal.pone.0012512.g006
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(changes in bold):
dx(t)
dt
~l{dx(t){(1-g) b1n1(t)zb2n2(t)zb1b2 min(n1(t), n2(t)) ½  x(t)
dy1(t)
dt
~(1-g)b1n1(t)x(t){d1y1(t){(1-g)b2n2(t)y1(t)
dy2(t)
dt
~(1-g)b2n2(t)x(t){d2y2(t){(1-g)b1n1(t)y2(t)
dy3(t)
dt
~(1-g) b2n2(t)y1(t)zb1n1(t)y2(t)zb1b2 min(n1(t), n2(t))x(t) ½  {d3y3(t)
dn1(t)
dt
~(1- ) k1y1(t)zk3y3(t) ½  {u1n1(t)
Figure 7. HBV and HDV viral dynamics. Number of uninfected cells (left), infected cells (middle), and viral loads (right). Initial viral loads of 400
copies/mL, d{1
i ~20 days and u{1
j ~92 hours, and no inhibition of the HBV viral production in cells infected with HBV and HDV.
doi:10.1371/journal.pone.0012512.g007
Figure 8. HBV and HDV viral dynamics. Number of uninfected cells (left), infected cells (middle), and viral loads (right). Initial viral loads of 400
copies/mL, d{1
i ~15 days, u{1
j ~92 hours and 90% inhibition of the HBV viral production in cells infected with HBV and HDV.
doi:10.1371/journal.pone.0012512.g008
HDV Viral Dynamics
PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12512dn2(t)
dt
~k2y3(t){u2n2(t)
Although the mechanism of the action of interferon-a, IFN, in
HDV patients is not clearly understood [32], some studies report
improvements in patients, with IFN efficacy as high as 90%
(g~0:9) [33]. Although lamivudine (LMV) does not have a direct
effect on HDV viral production k2 (notice the absence of (1{ ) in
the equations above) its effect on the viral production of HBV will
also have an effect on the HDV viral dynamics. Studies such as
[28] show efficacy levels of therapies based on LMV varying
between 90% to 99% ( w0:9) for the HBV infection.
With this in mind, we considered 5 different scenarios of
antiviral therapy responses for super-infected and co-infected
individuals in our simulations: two with monotherapies with LMV
and IFN alone and three others with LMV and three different
efficacy levels of IFN, i.e. ~0:95 and g~0 (LMV antiviral
therapy), ~0 and g~0:9 (IFN antiviral therapy) and ~0:95
Figure 9. HBV and HDV viral dynamics. Number of uninfected cells (left), infected cells (middle), and viral loads (right). Initial viral loads of 400
copies/mL, d{1
i ~15 days, u{1
j ~92 hours, and a 10% inhibition of the HBV viral production in cells infected with HBV and HDV.
doi:10.1371/journal.pone.0012512.g009
Figure 10. HBV and HDV viral dynamics. Number of uninfected cells (left), infected cells (middle), and viral loads (right). Initial viral loads of 400
copies/mL, d{1
i ~20 days, u{1
j ~92 hours, and no inhibition of the HBV viral production in cells infected with HBV and HDV.
doi:10.1371/journal.pone.0012512.g010
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These last three scenarios represent ones where LMV is very
efficient, but with different patient’s response levels to IFN.
Although the antiviral therapy responses for co-infected individ-
uals were less pronounced, the results were analogous in nature for
both types of infections; therefore, in the next five figures we only
present the results for the super-infection scenario where therapy
was applied for 168 days after the equilibrium of infection was
obtained. The results here presented are also based on di~92
hours, i~1, 2, 3, uj~20 days, j~1, 2, c~1, with all other
constants specified in the different graphs below. We decided to
omit a full discussion based on the effects of the different values
considered for the parameters in the antiviral therapy model, due
to the fact that the effects of these variations were the same as in
the previous section, and therefore we concentrate our discussion
on the new parameters of the model, g and .
In the graphs that follow, the vertical dashed lines in the middle
graph represent the beginning and the end of the antiviral therapy.
From the graphs, we observe the biphasic linear behavior of
HBV viral load as previously reported in [34,35] For the HBV
viral load a marked decrease in the first days of therapy is
observed, followed by a slower decrease. For HDV viral load,
there is very slow decrease in the beginning of the therapy, which
is not surprising due to what is believed about the no direct effect
of IFN and LMV in HDV patients. The slow decrease is followed
by a marked decrease, which becomes more and more parallel to
the viral load of HBV as the efficacy of IFN increases.
Figures 11 and 12 represent the dynamic behavior under
monotherapy with LMV and IFN, respectively. We observe that
even before the end of the therapy period, with only IFN, the
HBV viral load starts to increase (right graph of Figure 12). The
use of IFN alone seems to have only a momentary effect on the
decrease of the infection.
Notice that when an effective response to IFN therapy is
observed (values for gw0:5), as in Figure 13, the joint antiviral
therapy is able to decrease the viral load on an order of 10 at
the end of the therapy (from 105 for HDV and 104 for HBV only
with LMV, to 104 for HDV and 103 for HBV for the joint
therapy).
From the simulation study we realize that as g gets closer to 0.5
(g;0:5) as in Figure 14, the viral load behavior of HBV and HDV
infections gets closer to the case when we only apply the
lamivudine antiviral therapy (compare Figure 11 to Figures 13
and 14).
For the cases where IFN shows little efficacy (gƒ0:5), the viral
load dynamics of HBV and HDV is similar to the antiviral
monotherapy where only LMV is applied, such as in Figure 15.
However, in all cases there is a rebound of the infection when
the therapy is terminated. Again, this feature may represent an
artifact of this and other similar compartmental ODE models since
a complete clearance of the virus is not predicted. However, a
rebound of infection after ceasing treatment is a common
observation in IFN treated patients (for a review see [36]).
Discussion
Mathematical models represent useful tools to predict the
clinical course of virus diseases and the response to different
antivirus therapies. They have been previously used for a number
of human viruses, including HBV, HCV, and HIV [19–21]. In
this study, we describe, for the first time, a mathematical model for
HDV infection. Since production of HDV infective particles is
dependent on the simultaneous presence of HBV mathematical
modeling of HDV infection poses an additional degree of
complexity. Both HBV and HDV infect and replicate exclusively
in liver cells. Since HDV co-infects or super-infects exclusively
HBV infected individuals, the simultaneous behavior of both
HDV and HBV and the interaction between the two viruses is
considered according to the current knowledge of the biology of
the viruses and clinical course of the disease. Little is still known
about the mechanisms of HDV replication and its interaction of
HBV in vivo. The woodchuck model for HDV/HBV infection was
able to show some important tendencies on the clinical course of
HDV infection, both during co-infection and super-infection.
Figure 11. HBV and HDV viral dynamics during antiviral therapy. Number of uninfected cells (left), infected cells (middle), and viral loads
during the 168 days of antiviral therapy with LMV alone (right). Initial viral loads of 400 copies/mL, no inhibition of the HBV viral production in cells
infected with HBV and HDV and ~0:95.
doi:10.1371/journal.pone.0012512.g011
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therapy may largely differ between individuals and is believed to
be also dependent on a number of variables, including the
response of the immune system, which is still poorly understood.
Since in this work we did not consider modeling the immune
response of the host, the obtained results and conclusions shall be
interpreted with regard to this limitation.
Six variables were taken into account in the herein proposed
model: the number of uninfected cells, the number of HBV
infected cells, the number of HDV infected cells, the number of
cells simultaneously infected with HBV and HDV, the HBV viral
load, and the HDV viral load. Six differential equations were
obtained which were subsequently solved using the Matlab
software [23], and biological parameters previously described
and used by others [24–26,28,29,37] when modeling HBV
infection. The obtained numerical solutions were consistent with
those previously reported by others considering the HBV infection
alone [19,20,24,28]. In general, the predicted course of HDV
infection is similar to that observed for HBV. Given the same
initial viral loads of both viruses we observe a faster increase in the
Figure 13. HBV and HDV viral dynamics during antiviral therapy. Number of uninfected cells (left), infected cells (middle), and viral loads
during the 168 days of antiviral therapy with LMV and IFN (right). Initial viral loads of 400 copies/mL, no inhibition of the HBV viral production in cells
infected with HBV and HDV, ~0:95 and g~0:9.
doi:10.1371/journal.pone.0012512.g013
Figure 12. HBV and HDV viral dynamics during antiviral therapy. Number of uninfected cells (left), infected cells (middle), and viral loads
during the 168 days of antiviral therapy with IFN alone (right). Initial viral loads of 400 copies/mL, no inhibition of the HBV viral production in cells
infected with HBV and HDV and g~0:9.
doi:10.1371/journal.pone.0012512.g012
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peak, a small decrease in the HBV viral load and the number of
infected cells is observed followed by a stabilization of these
parameters of infection with small oscillations around what can be
considered as a plateau. Concerning HDV, the increase in the
number of infected cells and viral load is slower than the predicted
for HBV. Usually, the plateau is reached between 200 and 500
days after infection depending on the initial viral load. In most
tested scenarios, the number of HDV infected cells and viral load
values remain below corresponding predicted values for HBV.
The only exception is observed when an inhibitory factor c of
HBV replication is introduced during super-infection. This issue is
further discussed below. Previous studies aimed to evaluate HBV
and HDV activity in infected patients were mainly performed
using cross-sectional approaches together with qualitative analysis
or low sensitivity quantitative analysis [38–40]. This led often to
contradictory conclusions with some authors showing that HBV
replication may modulate HDV pathogenesis [39,41,42] and
others claiming that liver disease is mainly due to HDV infection
[38,43–46]. To our knowledge, a single quantitative longitudinal
Figure 15. HBV and HDV viral dynamics during antiviral therapy. Number of uninfected cells (left), infected cells (middle), and viral loads
during the 168 days of antiviral therapy with LMV and IFN (right). Initial viral loads of 400 copies/mL, no inhibition of the HBV viral production in cells
infected with HBV and HDV, ~0:95 and g~0:3.
doi:10.1371/journal.pone.0012512.g015
Figure 14. HBV and HDV viral dynamics during antiviral therapy. Number of uninfected cells (left), infected cells (middle), and viral loads
during the 168 days of antiviral therapy with LMV and IFN (right). Initial viral loads of 400 copies/mL, no inhibition of the HBV viral production in cells
infected with HBV and HDV, ~0:95 and g~0:7.
doi:10.1371/journal.pone.0012512.g014
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patients, has been until now reported [47]. The authors show
different replication profiles of HBV and HDV including
fluctuating activities of both viruses with alternate predominance
across 4–8 year periods of monitorization. Although these
oscillations were also predicted by the present model further
clinical studies are mandatory to confirm this observation.
Concerning the HDV infection, whether the co-infection or
super-infection of HBV infected liver cells, we decided to consider
different values for the biological parameters tested. A sensitive
analysis was performed taking into account the data reported by
other groups concerning both experimental animal infections and
monitorization of the course of infection in human patients in the
presence or absence of therapy. The parameters tested included
the initial viral loads for HBV and HDV, the virion half-life, and
the half-life of infected cells. The initial viral loads of an infected
individual did not significantly alter the overall course of infection
with the number of infected liver cells reaching a plateau which
seems to remain stable in the absence of any therapy. The only
noticed difference concerns the time needed to reach this plateau
which is shorter when the initial viral load is larger. In contrast, the
virion half-life and the time infected cells remain alive and thus
secreting new infectious virus particles showed to critically
influence the course of infection. We found that the combination
of these two parameters influences the speed at which the number
of HDV infected cells and HDV viral loads reach a plateau. In the
case of HBV, it was suggested that the mean life-span of free
virions in plasma could vary between 15 and 92 hours and the
half-life of infected cells could reach 100 days [28,37]. Since HBV
and HDV share the same envelope proteins we decided to test the
same values for the life-span of free virions. The half-life of HDV
and HBV infected liver cells was also tested in the range of 10–100
days since we considered that co-infection with both viruses would
not increase the half-life of cells when compared with the HBV
infection alone. Surprisingly, in our model variations in the values
of these two parameters showed to radically influence the possible
course of infection. In general, the longer the life-span of free
virions the faster the number of infected cells and free virions
reaches a plateau. A similar picture was found for the different
values of half-life of infected cells tested. Our simulation data
suggest that a biological relevant scenario is established for values
of half-lives of infected cells above 50 days or 20 days if the mean
life-span of free virions will be over 32 hours. Moreover, if the
mean half-life of infected cells is below 10 days, then the mean life-
span of free-virions should be over 118 hours in order to be
possible to observe an increase in the overall number of infected
cells and HDV viral load. Since this value is higher than the mean
half-life of virions in plasma calculated by others (36.9 hrs; Tsiang
and Gibbs [24]) it is possible that a therapy directed to reducing
the half-life of infected cells below 10 days would significantly
increase virion clearance. Identical pictures were observed for both
the co-infection and super-infection scenarios. For values below
those indicated by our model it seems probable that a spontaneous
clearance of HDV infection would occur. However, to our
knowledge, this scenario was not until now observed. It has been
previously reported that during the acute phase of super-infection,
HDV actively replicates while, at the same time, HBV replication
is partially suppressed [48,49]. The degree of suppression of HBV
replication, however, remains largely speculative. We decided to
test the influence of HDV suppression of HBV replication by
introducing a new variable c in our model. The values of c tested
ranged from 0 (100% inhibition of HBV replication) to 1 (no
inhibition of HBV replication). In general, we observed that
variations in the values of c influenced the predicted relative
number of HBV and HDV viral loads and infected cells. For high
inhibition values of HBV replication (cƒ0:2) the number of HDV
infected cells and HDV viral load surpasses the number of HBV
infected cells and HBV viral load, respectively. This picture is not
observed when c is set to 1 (no inhibition) or when low inhibition of
HBV replication is considered (c§0:8).
The potential to predict the behavior of virus infections under
the presence of different antiviral therapies is one of the most
important issues in mathematical modeling. Accordingly, we
decided to test this model giving the most commonly used and
generally accepted therapy approaches for HDV infection. These
approaches are based on the use of nucleotide analogues, like
lamivudine or ribavirine, peggylated a-interferon or a combination
of both. Nucleotide analogues are known to inhibit HBV
replication with efficacies ranging between 90% and 99%, but
seem not to have any effect on HDV replication per se. The
detailed mechanisms of action of interferon-a are still controversial
but, in any case, it is generally accepted that it induces the
expression of a large number of cellular proteins some of which
have a direct antiviral effect. Moreover, interferon-a has been
implicated in the regulation of adaptative immune responses
(reviewed by [50]).
When tested alone, lamivudine showed to be able to reduce
significantly the HBV viral load (about 4 log in 150 days) although
a complete virus clearance could not be achieved. This may be due
to limitations of the model as noticed also by Tsiang and Gibbs
[24] when modeling HBV infection alone. The observed reduction
was biphasic with a first fast decrease in the beginning of treatment
and a second slower in the following weeks. This biphasic behavior
was previously reported for LMV treated patients [28]. Although
the present model does not predict such a marked biphasic
behavior, the decrease in the HBV viral load is clearly faster
during the first 15 days of treatment. The biphasic decline of HBV
viral load in patients under therapy aimed to inhibit virus
production has been previously reported by others (Tsiang et al.,
[35]). This biphasic behavior was not accommodated by the initial
model of HBV viral dynamics developed by Nowak et al. [37]. To
overcome this problem Tsiang et al (1999, [35]) introduced
modifications in the assumptions of the efficacy of inhibition of
viral infection. This enabled to show that increasing values of drug
efficacy result in an initial faster decline of viral load followed by a
slower second phase. The decline during the second phase was
found to be similar independent of the values of inhibition tested.
In contrast, concerning HDV, LMV seems to reduce the HDV
viral load with less efficiency. In this case, HDV virus clearance is
slow in the beginning of treatment and then seems to decay
exponentially.
In the case of LMV and interferon-a (IFN) combination
therapies we tested several scenarios that differed for the efficacy of
IFN. For low (30%) and medium (70%) interferon efficacies, the
combination therapy did not show a significant improvement in
reducing the viral load when compared to the LMV monotherapy.
However, if the efficacy of IFN is high (90%) the model predicts a
10 times reduction of HBV and HDV viral loads when compared
with LMV monotherapy and low or medium efficacy interferon-a
combination therapies. The same pattern was observed for both
co-infection and super-infection scenarios. In any case, we could
not observe a complete clearance of virus infection after 6 months
of therapy. Moreover, after ceasing therapy, a rebound of infection
was in all cases observed. Tsiang and Gibbs [24] reported a similar
behavior when modeling HBV dynamics alone. This may be due
to limitations of the present model since small amounts of free
virus particles are predicted to survive in plasma even after
prolonged treatment. In any case, we believe that further
HDV Viral Dynamics
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infection is crucial to clarify this question.
Modeling the scenario for IFN monotherapy showed a
significant decrease in the HDV viral load (w3 log in 150 days)
and the number of infected cells. However, in this scenario the
HBV viral load did not decrease significantly (v1 log in 150 days)
displaying what seems to be a tendency to stabilize at high levels
(w107 copies/mL).
Finally, both LMV monotherapy and combination therapy of
LMV and IFN were predicted to more effectively reduce the HBV
and HDV viral loads in the case of super-infection scenarios when
compared with the co-infection. In contrast, IFN monotherapy
was found to reduce the HDV viral load more efficiently in the
case of super-infection while the effect on the HBV viral load was
more pronounced during co-infection.
In conclusion, the combination LMV/IFN therapy seems to be
more effective in reducing the number of infected cells and viral
load of both viruses. LMV alone reduces the HBV viral load faster
when compared with HDV, and IFN monotherapy has a
significant effect in reducing solely the HDV viral load. In all
tested scenarios a rebound of infection could be observed after the
end of therapy.
Taken together, this model suggests that there is a need for
development of high efficacy therapeutic approaches towards the
specific inhibition of HDV replication. These approaches may
additionally be directed to the reduction of the half-life of infected
cells and life-span of newly produced circulating virions.
Further research is needed to overcome some of the limitations
of the mathematical model here proposed; namely, to date, most
of the constant parameters in the model are unknown for HDV
infections. The present work is just a first step in trying to
understand the HDV viral dynamics; however, a more in-depth
look is necessary to understand the different behavior regarding
co-infection and super-infection. The authors will continue their
work of modeling the dynamics of HDV through a hierarchical
Bayesian modeling approach. The main difference between this
approach and the one here presented, hierarchical Bayesian versus
mathematical, is that in a hierarchical Bayesian approach not only
are the parameters no longer fixed quantities, but instead random
quantities, their distribution depends on additional parameters,
called the hyperparameters. The posterior distribution represents
the uncertainty of the parameters after taking the data into
consideration. MCMC (Markov Chain Monte Carlo) methods
allow us to evaluate any characteristic of the posterior by
simulating many sample values from it and then approximating
any desirable characteristic from its corresponding sample value.
The latest developments of free software such as R [51] and
WinBUGS [52] overcame some of the difficulties in the
implementations of MCMC methods when fitting highly complex
models.
Bearing this in mind, and working together with clinicians, we
hope in the future to discover additional information regarding
viral dynamics of HDV and thus contribute to a better
understanding of this pathology during the different treatment
therapies.
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